Skip to main content Accessibility help
×
Home

COST-EFFECTIVENESS OF EXERCISE PROGRAMS IN TYPE 2 DIABETES

  • Doug Coyle (a1), Kathryn Coyle (a2), Glen P. Kenny (a3), Normand G. Boulé (a4), George A. Wells (a5), Michelle Fortier (a3), Robert D. Reid (a6), Penny Phillips (a7) and Ronald J. Sigal (a8)...

Abstract

Background: A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.

Methods: Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.

Results: The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.

Conclusions: A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.

Copyright

References

Hide All
1.Bertram, MY, Lim, SS, Barendregt, JJ, Vos, T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia. 2010;53:875881.
2.Boulé, NG, Haddad, E, Kenny, GP, Wells, GA, Sigal, RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. JAMA. 2001;286:12181227.
3.Brazier, J, Roberts, , Deverill, M. The estimation of a preference based measure of health from the SF36. J Health Econ. 2002;21:271292.
4.Briggs, A, Sculpher, M, Buxton, M. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ. 1994;3:95104.
5.Briggs, AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479500.
6.Brun, JF, Bordenave, S, Mercier, J, Jaussent, A, Picot, MC, Préfaut, C. Cost-sparing effect of twice-weekly targeted endurance training in type 2 diabetics: A one-year controlled randomized trial. Diabetes Metab. 2008;34:258265.
7.CADTH. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: CADTH; 2006.
8.Clarke, P, Gray, A, Holman, R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340349.
9.Clarke, PM, Gray, AM, Briggs, A, et al.A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 68) Outcomes Model. Diabetologia. 2004;47:17471759.
10.Coyle, D, Palmer, AJ, Tam, R. Economic evaluation of PioglitazoneHCl in the management of Type 2 Diabetes Mellitus in Canada. Pharmacoeconomics. 2002;20:3142.
11.Doubilet, P, Begg, CB, Weinstein, MC, et al.Probabilistic sensitivity analysis using Monte Carlo simulation: A practical approach. Med Decis Making. 1985;5:157177.
12.Eves, ND, Plotnikoff, RC. Resistance Training and Type 2 Diabetes. Considerations for implementation at the population level. Diabetes Care. 2006;29:19331941.
13.Goeree, R, Lim, ME, Hopkins, R, et al.Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. Can J Diabetes. 2009;33:3545.
14.Herman, WH, Hoerger, TJ, Brandle, M, et al.The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323332.
15.Lamy, A, Yusuf, S, Pogue, J, Gafni, A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 2003;107:960965.
16.Reid, RD, Tulloch, HE, Sigal, RJ, et al.Effects of aerobic exercise, resistance exercise or both, on patient-reported health status and well-being in type 2 diabetes mellitus: A randomised trial. Diabetologia. 2010;53:632640.
17.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:11831197.
18.Sapsford, R. Deputy Minister's response to the investigation into the Ministry of Health and Long-Term Care's decision-making concerning the funding of Avastin for colorectal cancer patients. Letter dated August 26th 2009.
19.Selvin, E, Marinopoulos, S, Berkenblit, G, et al.Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421431.
20.Sigal, RJ, Kenny, GP, Boulé, NG, et al.Effects of aerobic exercise, resistance exercise, or both on glycemic control in type 2 diabetes: A randomized trial. Ann Intern Med. 2007;147:357369.
21.Snowling, NJ, Hopkins, WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: A meta-analysis. Diabetes Care. 2006;29:25182527.
22.Stratton, IM, Adler, AI, Neil, HA, et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405412.
23.Thomas, DE, Elliott, EJ, Naughton, GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;3:CD002968.
24.van Hout, BA, Al, MJ, Gordon, GS, et al.Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 1994;3:309319.
25.Ware, JE, Snow, KK, Kolinski, M, Gandeck, B. SF-36 Health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Centre; 1993.

Keywords

COST-EFFECTIVENESS OF EXERCISE PROGRAMS IN TYPE 2 DIABETES

  • Doug Coyle (a1), Kathryn Coyle (a2), Glen P. Kenny (a3), Normand G. Boulé (a4), George A. Wells (a5), Michelle Fortier (a3), Robert D. Reid (a6), Penny Phillips (a7) and Ronald J. Sigal (a8)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed